Share Share Share

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

LEUKEMIA

Pavlasova, G; Borsky, M; Svobodova, V; Oppelt, J; Cerna, K; Novotna, J; Seda, V; Fojtova, M; Fajkus, J; Brychtova, Y; Doubek, M; Pospisilova, S; Mayer, J; Mraz, M, 2018: Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. LEUKEMIA 32(9), p. 2028 - 2031, doi: 10.1038/s41375-018-0211-0

Research Groups:

• Bioinformatics Core Facility
• Chromatin Molecular Complexes
• Microenvironment of Immune Cells

CEITEC authors:

• Václav Šeda, Ph.D.
• Miloslava Fojtová
• Prof. Jiří Fajkus
• Prof. Marek Mráz, Ph.D.